Search

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

From Finance to Pharma

The Role of Endocrinologists and PCPs in Diagnosing Chronic Kidney Disease

Mohamed Eid shares his perspective on the role endocrinologists and primary care professionals play in diagnosing chronic kidney disease.

The View from Both Sides of the Table

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Vision & Values

Yankees Legend Bernie Williams and Celebrity Vocal Coach Eric Vetro Harness the Power of Music with Tune In To Lung Health® for Interstitial Lung Disease Awareness

An extension of Boehringer Ingelheim’s Breathless® campaign, Tune In To Lung Health explores how music and breathing may help motivate, inspire, and support people living with interstitial lung disease (ILD) Program resources introduced during September’s

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

Talking drug discovery with our U.S. research site head, Carine Boustany

Learn about the challenges and victories of developing new medicine for conditions, like generalized pustular psoriasis (GPP) flares in adults.

Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office

Heart Failure

Deciphering Circuits in Neuroscience | Boehringer Ingelheim US

Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.

Oncology & Cancer Immunology

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

Oncology & Cancer Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.

Creating an Inclusive Workplace for Employees with Disabilities

HBA Rising Star & Luminary Awards | Boehringer Ingelheim US

Read more on the HBA, is a global nonprofit organization recognizing outstanding individuals and companies who impact and influence women in healthcare.

Cardiometabolic Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

From Finance to Pharma

The Role of Endocrinologists and PCPs in Diagnosing Chronic Kidney Disease

The View from Both Sides of the Table

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

Vision & Values

Yankees Legend Bernie Williams and Celebrity Vocal Coach Eric Vetro Harness the Power of Music with Tune In To Lung Health® for Interstitial Lung Disease Awareness

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

Talking drug discovery with our U.S. research site head, Carine Boustany

Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office

Heart Failure

Deciphering Circuits in Neuroscience | Boehringer Ingelheim US

Oncology & Cancer Immunology

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

Oncology & Cancer Immunology

Creating an Inclusive Workplace for Employees with Disabilities

HBA Rising Star & Luminary Awards | Boehringer Ingelheim US

Cardiometabolic Diseases

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism